Navigation Links
S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis
Date:10/18/2011

WELLESLEY HILLS, Mass.,  Oct. 18, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale.  S1P1 agonists are currently indicated for treatment of multiple sclerosis ("MS").

MS is the second most common cause of disability in young adults (after trauma) and affects approximately 350,000 – 450,000 people in the US and 1-2 million people worldwide.  The major unmet need in MS is agents with better safety and efficacy, especially in terms of halting the progression of disease and preventing or slowing disability.  Until recently, treatment for MS was generally directed in three areas; 1) reduction of acute exacerbations, 2) reduction of relapses/disability progression, or 3) symptomatic relief.  All of these first or second line therapies required injection or infusion, including the number one selling MS drug, Copaxone, which had sales of $2.6 Bil in 2010 and will face generic competition in 2014.  Worldwide sales for all MS drugs were $11.5 Bil in 2010 and expected to grow at a CAGR of 6% to almost $19 Bil by 2016.

Information above per EvaluatePharma®, Available WW Sales for Autoimmune Disorders and Multiple Sclerosis, Aug. 4, 2011.

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
2. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
3. Robotic Surgery Expert Dr. David Samadi, MD Discusses FDA Warnings on the Effect of GnRH Agonists
4. Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
7. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
8. New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS
9. New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes
10. NACDS, NCPA: Victory for Patients, Pharmacy as CMS Moves to Withdraw Provisions of AMP Rule Currently Blocked by Injunction
11. Intermittent Catheter Market Currently Valued at $230 Million and Set to Double by 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... According to a study conducted by Persistence Market Research ... CAGR of 6.5% during the forecast period 2016-2024. According to the ... the leading market for cryotherapy globally during the forecast period  ... Highlights from the Report  ... adequate supply of gas in order to provide smoother maintenance services ...
(Date:1/19/2017)... Jan. 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... specializing in the treatment of non-melanoma skin cancers ... superficial radiation therapy, today announced that it will ... financial results on Thursday, February 2, 2017 after the ... a conference call with the investment community on Thursday, ...
(Date:1/19/2017)... Pfizer joins Astex, AstraZeneca, ... Consortium   Major research investment to ...   The Milner Therapeutics Institute today ... a partner to the Milner Therapeutics Consortium. Pfizer has ... transfer of materials between industry and academia and allocation ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Remote Medical Technologies (RMT), the leader ... with their iMedHD2™ Portable Teleultrasound System. Compatible with any ultrasound ... HD, dynamic, streaming ultrasound images and video to one or more distant locations ...
(Date:1/19/2017)... ... 2017 , ... MB Business Capital, a division of MB ... to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing (“MedPro”). Proceeds ... MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided a new ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
(Date:1/19/2017)... ... 2017 , ... Tribble Insurance Agency, a family owned and operated firm offering ... charity event to honor Chad Phillip Dermyer, a local police trooper who was shot ... and his fellow officers were conducting routine stops of suspects when one of them, ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top ... Cynthia Murdock and Dr. Shaun Williams have each been chosen by their peers ...
Breaking Medicine News(10 mins):